Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0WESMY
ADC Name	WO2021147993A1 ADC-2
Synonyms	WO2021147993A1 ADC 2 Click to Show/Hide
Organization	Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Drug Status	Investigative
Indication	In total 2 Indication(s) Gastric cancer [ICD11:2B72] Investigative Pancreatic cancer [ICD11:2C10] Investigative
Drug-to-Antibody Ratio	6.59
Structure
	3D MOL	2D MOL
Antibody Name	PD3		Antibody Info
Antigen Name	Tumor-associated calcium signal transducer 2 (TACSTD2)		Antigen Info
Payload Name	Undisclosed
Linker Name	WO2021147993A1 ADC-2 linker

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 100	%	FaDu cells	Hypopharyngeal squamous cell carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 21)	High TROP2 expression (TROP2 +++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218

References

Ref 1	Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof; 2021-07-29.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.